Last Updated : July 17, 2019
Details
Generic Name:
ibrutinib
Project Status:
Not filed
Therapeutic Area:
Leukemia
Manufacturer:
Janssen Canada Inc.
Brand Name:
Imbruvica
Project Line:
Reimbursement Review
Project Number:
NS0005-000
Submission Type:
Non Submission
Fee Schedule:
N/A
Tumour Type:
Leukemia
Indications:
In combination with rituximab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL); In combination with obinutuzumab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)
Review Status:
Not Filed
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Clarification:
CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.
Last Updated : July 17, 2019